Potential for Genomics to Help Guide Preventive Strategies in Psychiatry.

Genomic testing for psychiatric prevention is not supported for population-wide screening, but targeted use—especially early in treatment—may improve diagnosis timing and monitoring.

• Why it matters: Evidence for net clinical benefit is lacking for broad primary prevention because risk differences are modest, individual prediction is limited, and psychological harm is possible.
• What they did: The Special Communication reviews potential benefits and harms of polygenic scores and rare-variant testing, emphasizing indicated prevention and early care within diagnostic uncertainty, plus pharmacogenomics for medication choice and safety.
• The result: Genomic information may be useful as a targeted clinical resource when results are communicated appropriately and integrated into ethically grounded care pathways, with added potential for addressing somatic comorbidity risk.

AI summary of the abstract · may contain errors · not medical advice · read the paper.